文献速递胃肠动力与功能性疾病

腹泻型肠易激综合征生物标志物检测的成本效益:面向支付方的评估框架

Cost Effectiveness of Biomarker Tests for Irritable Bowel Syndrome With Diarrhea: A Framework for Payers.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-03-27

该研究通过决策分析软件评估符合罗马IV标准腹泻型肠易激综合征的假设队列,比较常规诊疗与基于生物标志物的诊断路径。在支付意愿阈值10万美元/质量调整生命年下,生物标志物检测费用超过846美元时即便准确率100%也不具成本效益;概率分析显示不同费用对应不同准确率阈值方可具成本效益。

要点

  • 在10万美元/质量调整生命年支付意愿阈值下,生物标志物检测费用超过846美元时不具成本效益,即使检测准确率100%。
  • 概率分析中,多数模拟(≥75%)显示检测费用100美元需准确率51%、200美元需57%、300美元需63%方具成本效益。
  • 费用400、500、600、700、800美元时,对应准确率阈值分别为69%、76%、82%、89%、94%。

核心结论

  • 在符合罗马IV标准腹泻型肠易激综合征假设队列的决策分析中,识别出可指导生物标志物检测开发、验证、定价和报销的成本与准确率阈值。

研究设计与样本

  • 使用决策分析软件评估符合罗马IV标准腹泻型肠易激综合征的假设队列,开展成本效用和预算影响分析,比较常规诊疗与基于生物标志物的诊断路径,采用第三方支付方视角。

主要发现

  • 基础病例分析中,支付意愿阈值10万美元/质量调整生命年下,生物标志物检测费用超过846美元时不具成本效益,即使检测准确率100%。
  • 概率分析使用1000次模拟,多数模拟(≥75%)显示生物标志物诊断路径在以下准确率阈值以上具成本效益:100美元检测需51%准确率,200美元需57%,300美元需63%,400美元需69%,500美元需76%,600美元需82%,700美元需89%,800美元需94%。

关键数值与推荐

  • 生物标志物检测费用超过846美元时不具成本效益,即使准确率100%,支付意愿阈值为10万美元/质量调整生命年。
  • 100美元检测准确率≥51%、200美元≥57%、300美元≥63%、400美元≥69%、500美元≥76%、600美元≥82%、700美元≥89%、800美元≥94%时,多数模拟(≥75%)显示具成本效益。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Diagnosis of diarrhea-predominant irritable bowel syndrome (IBS-D) relies on the Rome IV symptom-based criteria, which are imperfect for separating functional vs organic disease. Biomarker tests for IBS-D might be added to symptom data to allow clinicians to make more accurate and precise diagnoses in a cost-effective manner. We tested the economic consequences of using a range of hypothetical IBS-D biomarkers, and explored at what cost and level of accuracy a biomarker becomes cost effective. We produced a framework for payers to evaluate the return on an investment of implementing IBS-D biomarkers of varying accuracy and cost. METHODS: We used decision analysis software to evaluate a hypothetical cohort of patients who met Rome IV criteria for IBS-D. We conducted cost-utility and budget impact analyses of 2 competing approaches: usual care or an IBS biomarker-based diagnostic approach. Patients in the usual care group received empiric IBS treatment; non-responders received additional diagnostic tests for organic disease. In the group evaluated with a biomarker test, those with a positive result received IBS treatment before additional diagnostic analyses, whereas patients with a negative result underwent upfront diagnostic testing. Outcomes were incremental cost per quality-adjusted life year gained (third-party payer perspective) and incremental per-member per-month cost. RESULTS: In the base-case analysis, using a willingness-to-pay threshold of $100,000/quality-adjusted life year, we found that biomarkers are not cost effective when the biomarker test costs more than $846, even if the test is 100% accurate in detecting IBS-D. In probabilistic analysis using 1,000 simulations, most trials (75% or more) show that the biomarker-based diagnostic approach is cost effective above the following accuracy thresholds: a $100 biomarker test with 51% accuracy, a $200 test with 57% accuracy, a $300 test with 63% accuracy, a $400 test with 69% accuracy, a $500 test with 76% accuracy, a $600 test with 82% accuracy, a $700 test with 89% accuracy, and a $800 test with 94% accuracy. CONCLUSIONS: In decision analysis of a hypothetical cohort of patients who met Rome IV criteria for IBS-D, we identified cost and accuracy thresholds that can guide investigators and payers as they develop, validate, price, and/or reimburse IBS-D biomarker tests for use in everyday clinical practice.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Almario CV, Noah BD, Jusufagic A, et al. Cost Effectiveness of Biomarker Tests for Irritable Bowel Syndrome With Diarrhea: A Framework for Payers. Clin Gastroenterol Hepatol. 2018. PMID: 29596984. doi:10.1016/j.cgh.2018.03.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。